IL-6 has been reported to promote cell proliferation [17–20], affect insulin growth factor (IGF), and result in insulin growth factor binding protein (IGFBP) 3 inhibition, thereby contributing to an environment favoring tumor proliferation in patients with NSCLC [21, 22]. Here, IL6 is linked to non-small cell lung carcinoma.